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Introduction
During the 2020 European Respiratory Society 
(ERS) International Congress, the author of the 
best abstract (highest average score of abstract 
reviewers and only those who had not applied or 
were not eligible for a sponsored award) of every 
Assembly was awarded “a best-abstract certificate”. 
Best-abstract awardees were invited to write a short 
summary about their virtual Congress experience 
and their view on the evolving field of research in 
light of their respective ERS Assembly. The purpose 
of this article is to give the readers a quick overview 
of some of the Congress highlights and to give the 
stage to the promising best-abstract awardees as 
they are the future of the ERS.
Assembly 2: Respiratory 
Intensive Care (Noel Britton)
Given the overwhelming challenge that coronavirus 
disease 2019 (COVID-19) has presented in 2020, 
it was fitting that much of Respiratory Intensive 
Care Assembly Congress content was related to 
describing patients with COVID-19 and how to 
care for them.
During the Hot Topic session on intensive care, 
Prof. Alexandre Demoule showed that patients 
in racial and ethnic minority groups were 
overrepresented in the clinical sample compared 
to white people [1], which was likely due to 
socioeconomic factors including access to care rather 
than biological factors. While the majority of patients 
(75–85%) with COVID-19 were overweight or obese, 
the rate of patients with a comorbidity or risk factor 
associated with respiratory disease (smoking status, 
COPD, etc.) was lower than expected in patients with a 
severe respiratory infection . Mortality rates have been 
highly variable globally, but are estimated to be >30% 
for patients receiving care in the intensive care unit.
Older adults (aged >65 years) presented earlier 
in the disease course and with symptoms atypical 
of COVID-19 including falls, confusion, syncope 
and heart failure, and were more likely to have 
atypical findings on chest computer tomography 
(CT) imaging [1, 2]. Ground-glass opacities mixed 
with peripheral consolidations were common CT 
findings in older adults and these were associated 
with high mortality rates [3].
Much of the discussions, taking place around 
the care of patients with COVID-19, were about 
the treatment of hypoxaemia and appropriate 
ventilation. Many investigators presented single site 
observational studies examining the use of different 
ventilation methodologies including high-flow nasal 
cannula, different types of continuous positive 
airway pressure (CPAP) utilisation and mechanical 
ventilation settings. In the “Management of COVID-
19” session, Prof. Paolo Navalesi presented a 
comprehensive review of the existing literature 
about pre-ventilation, noninvasive ventilation, 
mechanical ventilation and extracorporeal 
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membrane oxygenation (ECMO). In the Hot Topic 
session on intensive care, Prof. Stefano Nava 
shared data about the risk of viral transmission 
associated with different ventilation methodologies. 
There is agreement that there is enough data to 
provide clear conclusions about best practices for 
treatment of patients with COVID-19 requiring 
assisted ventilation and that further investigation 
is required to develop clinical guidelines and 
recommendations.
Assembly 4: Sleep and 
Breathing Disorders; 
and Clinical Physiology 
(Amany F. Elbehairy)
During the 2020 ERS International Congress, the 
link between obstructive sleep apnoea (OSA) and 
exercise intolerance was highlighted. Speakers in 
the “Exercise and sleep: from impaired function to 
new therapeutic strategies” symposium discussed 
the interactions between sleep and exercise from 
health-to-disease. Prof. Ludger Grote outlined the 
available data on reduced exercise capacity in OSA 
patients, a finding that was confirmed by recent 
meta-analyses [4, 5]. In this perspective, Elbehairy 
et al. [6] have shown that OSA-associated resting 
systemic vascular dysfunction and pulmonary gas-
exchange abnormalities during exercise are possible 
contributors for reduced exercise capacity and 
exertional dyspnoea.
Cardiovascular abnormalities are commonly 
associated with OSA. However, there was a debate 
after the ISAACC trial (Impact of Sleep Apnoea 
syndrome in the evolution of Acute Coronary 
syndrome. Effect of intervention with CPAP) 
results showing that, in non-sleepy patients 
with acute coronary syndrome (ACS), OSA was 
not associated with an increased prevalence 
of cardiovascular events [7]. On the contrary, 
a secondary analysis of the RICCADSA trial 
(Randomised Intervention with CPAP in Coronary 
Artery Disease and Sleep Apnoea) [8] showed that 
untreated OSA is an independent risk factor for 
major adverse cardiovascular/cerebrovascular 
events in revascularised patients with ACS. OSA has 
also been found to be an independent risk factor 
for faster expansion of thoracic aortic aneurysm 
over 3 years after controlling for blood pressure 
and baseline diameter [9].
In clinical physiology, a few studies presented 
during the ERS Congress have focused on assessing 
inspiratory neural drive (IND) using diaphragm 
electromyography. IND measurement provides 
a comprehensive insight into the mechanisms 
of dyspnoea and enables a more detailed 
mechanistic assessment of pharmacological and 
non-pharmacological therapeutic interventions 
in cardio-respiratory diseases. Domnik et al. [10] 
have shown that increased awake IND in COPD 
(compared with controls) fell significantly during 
sleep with unaltered inspiratory effort. In addition, 
evening bronchodilation was found to be able 
to induce sustained overnight improvements in 
dynamic respiratory mechanics and IND in COPD 
[11]. Furthermore, neuro-mechanical uncoupling 
during inspiratory loading was found to be greater 
in COPD-heart failure compared with COPD alone 
[12] and James et al. [13] have found that increased 
exertional dyspnoea intensity in mild COPD with 
low diffusing capacity could be explained by 
increased IND and reduced ventilatory efficiency. 
These studies have enriched our knowledge that 
measuring IND ultimately helps to better inform 
clinical approaches targeted at improving dyspnoea 
and/or exercise tolerance in various cardio-
respiratory diseases.
Assembly 7: Paediatrics 
(Sara M. Mensink-Bout)
The results of many studies related to the theme 
of “Early life origins of respiratory diseases” were 
presented in the Paediatric Assembly. These 
included studies showing that a higher exposure 
to air pollutants in infancy was associated with an 
impaired lung function until adolescence [14, 15], 
studies that linked an early-life suboptimal dietary 
intake to an adverse respiratory health later in life 
[16, 17] and a study that showed that a reduced 
fetal length in the first trimester of pregnancy was 
linked to earlier onset of asthma in childhood [18]. 
In a symposium and a state-of-the-art session on 
“Paediatric Respiratory Diseases” it was emphasised 
by Prof. Alvar Agusti Garcia-Navarro and Prof. Peter 
Sly that lung function grows along trajectories which 
still need a better understanding, since a low lung 
function early in life is related to an increased risk 
of all types of respiratory and even non-respiratory 
diseases, such as cardiovascular diseases and 
mortality in later life. Furthermore, Prof. Sejal Saglani 
presented that one of the factors that can potentially 
affect the long-term lung function outcomes is the 
manipulation of the airway microbiome through 
early allergen exposure.
In the “Paediatric Year in Review”, an overview of 
the results of important studies on asthma in the 
past year were presented by Prof. Klaus Bonnelykke, 
including that: vitamin D supplementation during 
pregnancy seems to prevent preschool asthma 
symptoms, but not school-age asthma or reduced 
lung function [19]; airway microbiota and the 
candidate gene GSDMB (encoding gasdermin-B) 
might play a role in childhood asthma development 
[20, 21]; and asthma-like symptoms in childhood 
were related to a doubled risk of COPD in adulthood 
[22]. In the symposium on current paediatric asthma 
guidelines, the evidence of the paradigm shift to 
recommend earlier treatment with as-needed low-
dose corticosteroids in children with mild asthma, 
proposed by Global Initiative for Asthma (GINA), 
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was discussed by Dr Louise Fleming. It was also 
mentioned by Dr James Paton and Dr Erick Forno 
that a shift to a more personalised medicine is 
needed, especially for obese children with asthma as 
a 5–10% reduction of weight can improve asthma 
outcomes.
In summary, the ERS Congress highlighted 
evidence that early life is of importance for 
respiratory outcomes later in life. A better 
understanding of the causal factors of chronic 
respiratory diseases may lead to better prevention 
and treatment throughout the life course.
Assembly 9: Allied 
Respiratory Professionals 
(Astrid Blondeel)
The 2020 ERS International Congress provided 
an interesting virtual programme for Assembly 9. 
In the symposium on “Exercise and sleep”, it was 
shown that several mechanisms are responsible for 
the positive effects of moderate intense exercise 
on sleep physiology (i.e. increase in sleep time, 
increase in deep sleep and decrease of rapid eye 
movement sleep) [23]. In patients with OSA, a 
combined treatment strategy is needed, including 
physical activity and exercise training, aiming to 
also address the cardiovascular and metabolic risk 
[24]. The symposium on “Frailty in chronic lung 
diseases” highlighted that frailty is not a disease, 
but rather a complex, multidimensional syndrome. 
The importance of personalised interventions was 
discussed, with the main focus on preserving 
physical function [25]. Frailty is common in 
patients with COPD (point prevalence of 10% in 
the Rotterdam study) and is related to a lower 
quality of life and increased risk for hospitalisation 
[26]. Pulmonary rehabilitation has a positive effect 
on preventing and reversing frailty, but targeting 
the rehabilitation to individual needs is crucial 
and therefore a comprehensive, multidisciplinary 
assessment is warranted [27].
Several exciting oral presentations discussed the 
feasibility and effect of diverse training modalities 
(e.g. game-based approach in patients with primary 
ciliary dyskinesia [28], whole-body vibration in 
patients with severe COPD [29], home-based 
rehabilitation in asthma [30]), physical activity 
coaching (e.g. after hospitalisation for COPD 
exacerbation [31]) and recovery to training [32] 
in patients with chronic lung diseases in all types 
of clinical settings. Interesting findings of tele-
rehabilitation and physical activity coaching in 
COPD were debated in the ALERT (Abstracts Leading 
to Evolution in Respiratory Medicine) session on 
rehabilitation by Dr Narelle Cox and Astrid Blondeel. 
Telerehabilitation in COPD was shown to be safe 
and can be provided if centre-based pulmonary 
rehabilitation is not available [33]. Physical activity 
coaching on top of pulmonary rehabilitation 
improves the patient’s experienced amount of daily 
life activities [34].
Finally, in the symposium on “Fear and anxiety 
in chronic lung disease”, Ron, a patient with 
idiopathic pulmonary fibrosis (IPF), discussed his 
feelings of fear and anxiety regarding his diagnosis. 
Addressing psychological needs is important, as 
anxiety and depression are common in patients 
with respiratory diseases [35]; but also disease-
specific fears (e.g. fear of dyspnoea or activity 
avoidance) should be taken into account, as they 
can negatively affect the outcomes of pulmonary 
rehabilitation [36]. Cognitive behaviour therapy, as 
a stand-alone intervention delivered by a respiratory 
nurse specialist, was found to improve symptoms 
of anxiety and decrease hospital admissions in 
patients with COPD [37]. Healthcare professionals 
can play an important role in patients’ well-being, 
as discussed by Debra Reynolds-Sandford in her 
talk on expressing empathy. It positively affects 
patients’ outcomes, which was endorsed by the 
statement of Ron.
Assembly 11: Thoracic 
Oncology (Yuanling Liu)
The 2020 ERS International Congress provided 
the latest developments in lung cancer screening, 
diagnostics, treatment and molecular biology. 
Jan Van Meerbeeck gave an overview on lung 
cancer screening to kick off the Congress in the 
joint ERS/Industry session “Frontiers of lung cancer 
screening”. In the “New perspectives in chest 
imaging: back to the future?” symposium on lung 
cancer screening, Hans-Ulrich Kauczor showed 
that the nodule in the lung under an ultralow-dose 
(sub-millisievert) CT was still easily visualised [38]. 
There have been some investigations performed to 
evaluate the accuracy of ultralow radiation dose CT 
of the chest. For detection of a nodule ≥5 mm, the 
sensitivity of ultralow radiation dose CT was 97.3% 
across all nodule types [38].
Lung cancer diagnostics and treatment is rapidly 
evolving. Song et al. [39] showed that circulating 
tumour DNA (ctDNA) clearance during treatment 
may serve as a predictive and prognostic marker 
across a wide spectrum of treatment regimens. 
Blood tumour mutational burden (bTMB) was 
used to evaluate the effect of treatment, and Rizvi 
et al. [40] reported that among 809 patients with 
evaluable bTMB, those with a bTMB ≥20 mutations 
per megabase showed improved overall survival for 
programmed death-ligand 1 (PD-L1) blockade via 
anti-PD-L1 antibody durvalumab plus cytotoxic 
T-lymphocyte-associated antigen 4 blockade with 
tremelimumab versus chemotherapy.
The relationship between the lung cancer 
microenvironment and the lung microbioma 
is currently a hot topic. Zitvogel et al. [41] 
showed that the microbiome might be involved 
in oncogenesis and immune activation to induce 
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tumour suppression. Nejman et al. [42] undertook 
an analysis of the microbiome of 1526 tumours and 
their adjacent normal tissues across seven cancer 
types, including breast, lung, ovary, pancreas, 
melanoma, bone and brain tumours. They found 
that different tumour types have distinct microbial 
compositions. In this Hot Topic session, Hortense 
Slevogt highlighted that integration of microbiome 
modulation in a microenvironment-targeting 
combination offered new directions for cancer 
immunotherapy.
Finally, abstracts presented about the biological 
aspects of lung cancer highlighted the role of 
novel mediators, such as extracellular vesicles and 
exosomes. Mansouri et al. [43] emphasised the role 
of extracellular vesicles in chemotherapy-induced 
lung metastasis. Furthermore, Liu et al. [44] showed 
that exosomes from intermittent hypoxia-treated 
lung adenocarcinoma cell lines upregulate PD-L1 
expression through the hypoxia-inducible factor-1α 
pathway in macrophages.
Concluding remarks
We hope to reach out to and inspire all clinicians 
and researchers to submit an abstract for the 2021 
ERS International Congress as this gives them an 
opportunity to be elected as the 2021 best-abstract 
awardee of their Assembly. Abstract submission is 
open until mid-February 2021. Good luck and we 
hope to see all of you in person in Barcelona!
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